Q32 Bio completes enrollment in Part B of SIGNAL-AA Phase 2a trial; exceeds target to 33 patients

Q32 Bio Inc.

Enrollment completed in Part B of SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata.
Enrollment exceeded initial target of ~20 patients, total 33 patients enrolled due to patient demand.
Part B includes loading regimen (200mg weekly x4 then every other week) with 36-week dosing; topline data expected mid-2026.
Preliminary PK data shows steady state achieved earlier with loading regimen; signs of clinical activity observed among early patients.
Company plans to advance to pivotal trials pending Part B results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.